Compare PSKY & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSKY | VTRS |
|---|---|---|
| Founded | 1914 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Broadcasting | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 18.3B |
| IPO Year | N/A | 2019 |
| Metric | PSKY | VTRS |
|---|---|---|
| Price | $9.93 | $15.32 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 13 | 4 |
| Target Price | $12.92 | ★ $13.50 |
| AVG Volume (30 Days) | 6.9M | ★ 8.1M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | 1.93% | ★ 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $5.66 | $4.41 |
| Revenue Next Year | $1.34 | $1.96 |
| P/E Ratio | ★ N/A | $101.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.62 | $8.63 |
| 52 Week High | $20.86 | $17.53 |
| Indicator | PSKY | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.95 | 41.18 |
| Support Level | $8.63 | $12.90 |
| Resistance Level | $11.26 | $16.51 |
| Average True Range (ATR) | 0.49 | 0.45 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 13.39 | 25.45 |
Paramount Global operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount's streaming platforms is created by the production studios housed within the firm's other two business segments.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.